HZHongxin ZhaoMD, MPHSlidesetHIVChinese HIV Clinical Forum 2018Long-term HIV treatment: The Importance of Initial Antiretroviral Regimen Selection- Hongxin Zhao, MD, MPHView Slideset
CHChien-Ching HungMD, PhDSlidesetHIVChinese HIV Clinical Forum 2018Taiwan’s Experiences with Integrase Inhibitors- Chien-Ching Hung, MD, PhDView Slideset
SlidesetHIVChinese HIV Clinical Forum 2018Abstract-driven presentation: Efficacy and Safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in Virologically Suppressed Asian Adults with Renal Impairment: 144 Week- Ning LiView Slideset
SlidesetHIVChinese HIV Clinical Forum 2018Optimal use of integrase inhibitors in routine clinical practice- Kees Brinkman, MD, PhDView Slideset
KBKees BrinkmanMD, PhDSlidesetHIVChinese HIV Clinical Forum 2018Optimal use of integrase inhibitors in routine clinical practice- Kees Brinkman, MD, PhDView Slideset
SlidesetHIVChinese HIV Clinical Forum 2018Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhDView Slideset
SlidesetHIVChinese HIV Clinical Forum 2018Abstract-driven presentation: Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Treatment-Naïve Asian Adults: Week 144 results- Tina ZhengView Slideset
CBCharles BoucherMD, PhDSlidesetHIVChinese HIV Clinical Forum 2018Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhDView Slideset
SlidesetHIVChinese HIV Clinical Forum 2018HIV integrase Inhibitors: A novel mechanisms of action- Dr. H. WuView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018What is the Pharmacological support for reduced drug regimens?- Esteban Ribera, MD, PhDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018Integrating novel delivery systems/novel drugs- Maria Luisa Montes, MD, PhDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018Clinical Case presentation- Antonio Antela, MDView Slideset
